Bovine Atelocollagen Skin Sensitization Test

Last updated: July 30, 2024
Sponsor: AscentX Medical, Inc.
Overall Status: Trial Not Available

Phase

N/A

Condition

N/A

Treatment

Bovine atelocollagen intradermal injection

Clinical Study ID

NCT05235087
21-ASMI-101
  • Ages > 18
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Bovine atelocollagen skin testing of healthy adult volunteers to investigate the potential of allergy to atelocollagen medical device implants

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Healthy volunteers, of either sex, aged at least 18 years.

  • Volunteers must be capable of understanding and following directions in English.

  • Subjects who are healthy and have normal skin on the volar surface of the forearm.

  • Subjects willing and able to comply with the requirements of the study.

  • Subjects willing and able to comply with the follow-up requirements.

  • Subjects willing and able to give written and verbal informed consent.

Exclusion

Exclusion Criteria:

  • Subjects who are pregnant, nursing or intend to become pregnant.

  • Current treatment by a physician for allergy, unless physician consulted byInvestigator and participation was approved.

  • Participation in a repeat insult patch test (RIPT), skin prick test (SPT) orfollow-up work within the last month.

  • Recent immunization, including COVID-19 (less than 14 days prior to skin test).

  • Subjects who have had any form of collagen soft tissue treatment within the last 12months.

  • Subjects with medical history indicating atopy or dermatographia ('skin writing').

  • Subject has a current skin disease of any type apart from mild facial acne (e.g.,eczema, psoriasis).

  • Subject has any skin pathology or condition that could interfere with the evaluationof the treatment areas.

  • Subjects who were or are currently being treated with any systemicimmuno-suppressive therapy, including but not limited to chemotherapy agents orcortico-steroids (including inhaled or insufflated) within the past 3 months.

  • Subjects who were or are currently being treated with any topical OTC drug orprescription therapy on their arms (below the elbow) within the past 3 months.

  • Subjects with a history indicative of abnormal immune function (e.g., auto- immunediseases, HIV, cancer, etc.).

  • Subjects with known lidocaine hypersensitivity.

  • Subjects with known sensitivity to bovine collagen.

  • Subjects who have a history of dietary beef allergy, undergoing desensitization tobeef products or planning to undergo desensitization within the study evaluationperiod.

  • Subjects with severe allergies manifested by a history of anaphylaxis.

  • Subject is currently enrolled in an investigational drug or device study.

Study Design

Treatment Group(s): 1
Primary Treatment: Bovine atelocollagen intradermal injection
Phase:
Study Start date:
May 01, 2023
Estimated Completion Date:
December 01, 2023

Study Description

Day 01: Receive 0.1 mL intradermal injection of atelocollagen skin test into left volar forearm.

Day 15: Receive 2nd intradermal injection of 0.1 mL atelocollagen skin test into right volar forearm (14 days after 1st injection).

Day 45: Final assessment of both injection sites (30 days after 2nd injection)

Note: ALL injection sites will be assessed clinically at 30 minutes (for observational purposes) and at 72 hours (to determine response) after each injection. Visit windows for 72 hour assessments, and Day 15 and Day 45 visits can occur up to 96 hours (4 days) after target time.

Connect with a study center

  • Dermatology Institute

    Chula Vista, California 91910
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.